| Survival with olaparib in metastatic castration-resistant prostate cancer M Hussain, J Mateo, K Fizazi, F Saad, N Shore, S Sandhu, KN Chi, ... New England Journal of Medicine 383 (24), 2345-2357, 2020 | 728 | 2020 |
| Docetaxel-resistance in prostate cancer: evaluating associated phenotypic changes and potential for resistance transfer via exosomes C Corcoran, S Rani, K O’Brien, A O’Neill, M Prencipe, R Sheikh, G Webb, ... PloS one 7 (12), e50999, 2012 | 517 | 2012 |
| Intracellular and extracellular microRNAs in breast cancer C Corcoran, AM Friel, MJ Duffy, J Crown, L O'Driscoll Clinical chemistry 57 (1), 18-32, 2011 | 299 | 2011 |
| Exosomes from triple-negative breast cancer cells can transfer phenotypic traits representing their cells of origin to secondary cells K O’Brien, S Rani, C Corcoran, R Wallace, L Hughes, AM Friel, ... European journal of cancer 49 (8), 1845-1859, 2013 | 261 | 2013 |
| miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity K O'brien, MC Lowry, C Corcoran, VG Martinez, M Daly, S Rani, ... Oncotarget 6 (32), 32774, 2015 | 254 | 2015 |
| miR‐34a is an intracellular and exosomal predictive biomarker for response to docetaxel with clinical relevance to prostate cancer progression C Corcoran, S Rani, L O'Driscoll The Prostate 74 (13), 1320-1334, 2014 | 252 | 2014 |
| Characterisation and manipulation of docetaxel resistant prostate cancer cell lines AJ O'Neill, M Prencipe, C Dowling, Y Fan, L Mulrane, WM Gallagher, ... Molecular cancer 10, 1-13, 2011 | 238 | 2011 |
| Optimised Pre-Analytical Methods Improve KRAS Mutation Detection in Circulating Tumour DNA (ctDNA) from Patients with Non-Small Cell Lung Cancer (NSCLC) JL Sherwood, C Corcoran, H Brown, AD Sharpe, M Musilova, ... PloS one 11 (2), e0150197, 2016 | 175 | 2016 |
| A Phase I Open-Label Study to Identify a Dosing Regimen of the Pan-AKT Inhibitor AZD5363 for Evaluation in Solid Tumors and in PIK3CA-Mutated Breast and … U Banerji, EJ Dean, JA Perez-Fidalgo, G Batist, PL Bedard, B You, ... Clinical Cancer Research 24 (9), 2050-2059, 2018 | 136 | 2018 |
| Isolation of exosomes for subsequent mRNA, MicroRNA, and protein profiling S Rani, K O’Brien, FC Kelleher, C Corcoran, S Germano, MW Radomski, ... Gene Expression Profiling: Methods and Protocols, 181-195, 2011 | 135 | 2011 |
| Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer LM Smyth, K Tamura, M Oliveira, EM Ciruelos, IA Mayer, MP Sablin, ... Clinical Cancer Research 26 (15), 3947-3957, 2020 | 97 | 2020 |
| miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer C Corcoran, S Rani, S Breslin, M Gogarty, IM Ghobrial, J Crown, ... Molecular cancer 13, 1-12, 2014 | 93 | 2014 |
| Relevance of circulating tumor cells, extracellular nucleic acids, and exosomes in breast cancer AM Friel, C Corcoran, J Crown, L O’Driscoll Breast cancer research and treatment 123, 613-625, 2010 | 92 | 2010 |
| BEECH: a dose-finding run-in followed by a randomised phase II study assessing the efficacy of AKT inhibitor capivasertib (AZD5363) combined with paclitaxel in patients with … NC Turner, E Alarcón, AC Armstrong, M Philco, YAL Chuken, MP Sablin, ... Annals of Oncology 30 (5), 774-780, 2019 | 86 | 2019 |
| Tumor genomic testing for> 4,000 men with metastatic castration-resistant prostate cancer in the phase III trial PROfound (Olaparib) M Hussain, C Corcoran, C Sibilla, K Fizazi, F Saad, N Shore, S Sandhu, ... Clinical Cancer Research 28 (8), 1518-1530, 2022 | 76 | 2022 |
| Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors S Rani, C Corcoran, L Shiels, S Germano, S Breslin, S Madden, ... Cancer research 74 (14), 3821-3833, 2014 | 58 | 2014 |
| Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from> 4000 men with metastatic castration-resistant prostate cancer … JS De Bono, K Fizazi, F Saad, N Shore, SK Sandhu, N Mehra, M Kolinsky, ... Annals of Oncology 30, v328-v329, 2019 | 51 | 2019 |
| Detection of BRCA1, BRCA2, and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound KN Chi, A Barnicle, C Sibilla, Z Lai, C Corcoran, JC Barrett, CA Adelman, ... Clinical Cancer Research 29 (1), 81-91, 2023 | 47 | 2023 |
| MiR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget, 6 (32): 32774-32789 K O'Brien, MC Lowry, C Corcoran, VG Martinez, M Daly, S Rani, ... | 33 | 2015 |
| Concordance of BRCA1, BRCA2 (BRCA), and ATM mutations identified in matched tumor tissue and circulating tumor DNA (ctDNA) in men with metastatic … KN Chi, A Barnicle, C Sibilla, Z Lai, C Corcoran, JA Williams, JC Barrett, ... Journal of Clinical Oncology 39 (6_suppl), 26-26, 2021 | 28 | 2021 |
